Analyst Price Targets — HOWL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 19, 2025 2:32 pm | — | Wedbush | $1.00 | $0.69 | TheFly | Wedbush downgrades Werewolf Therapeutics to Neutral on challenging path |
| April 3, 2024 2:32 am | Reni Benjamin | JMP Securities | $12.00 | $6.06 | StreetInsider | JMP Securities Starts Werewolf Therapeutics Inc. (HOWL) at Market Outperform, 'PREDATOR Platform Unleashes Cytokine Biology to Kill Cancer' |
Latest News for HOWL
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HOWL.
U.S. House Trading
No House trades found for HOWL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.